ClinicalTrials.gov record NCT04252001
Growing up With the Young Endocrine Support System (YESS!)
Growing up With the Young Endocrine Support System (YESS!): Innovative E-technology to Improve Transition From Paediatric to Adult Care
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
A randomized study for 15–20-year-olds with chronic endocrine conditions that tests a smartphone/tablet game (YESS!), a control game, a paper toolkit, or usual care to support the move from paediatric to adult endocrine services. Key gates: age 15–20, having a mobile phone or tablet, and ability to use the app (participants with intellectual disability or language barriers that prevent game use are excluded). Participants complete questionnaires at baseline, 6 and 12 months; the main measure is a self-management questionnaire at 12 months and clinic drop-out in the first year after transfer.
What it is studying. Whether playing the YESS! smartphone/tablet game combined with a paper transition toolkit leads to a larger change in medical self-management (measured by the STARx questionnaire at 12 months) and a different drop-out rate from adult endocrine outpatient care, compared with a control game plus toolkit, toolkit alone, or usual care.
What the researchers hope to learn. To learn if the YESS! game plus toolkit can improve medical self-management scores during the first year of transition and to measure its effect on drop-out from adult endocrine outpatient care compared with other approaches.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game.
Interventions being studied
Being studied in this trial does not mean the treatment or procedure is approved or available for this condition.
- Device
- YESS! game
- Snake '97
- Other
- Transition-toolkit
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Aged 15 to 20 years old.
- Diagnosed with congenital adrenal hyperplasia, hypogonadotropic hypogonadism, Turner syndrome, Klinefelter syndrome, growth hormone deficiency, combined pituitary hormone deficiency, Androgen insensitivity syndrome, thyroid dysgenesis or Addison's disease
Exclusion criteria
- Lack of a mobile phone or tablet.
- Intellectual disability or language barrier leading to inability to use the YESS! game or the control game.
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
Rationale: Transition from paediatric to adult endocrinology is a challenge for adolescents, families and doctors. Up to 25% of young adults with chronic endocrine disorders are lost to follow-up ('drop-out') once the young adult moves out of paediatric care. Non-attendance and sub-optimal medical self-management can lead to serious and expensive medical complications. In a pilot study, adolescents suggested the use of e-technology to become more involved in the transition process. The investigators have designed and developed the YESS! game, a tool to help improve medical self-management in adolescents with chronic endocrine disorders. The hypothesis is that adolescents playing the YESS! game will show a larger increase in self-management score during the first year of transition and will have a lower drop-out rate at the adult endocrine outpatient clinic (OPC), compared to adolescents who do not play the game. Objective: 1.To improve medical self-management. 2.To prevent drop-out from the adult outpatient clinic. Study design: multicentre randomized controlled trial Study population: 160 transition patients from 15 to 20 years old from the participating countries Spain, The United Kingdom, Belgium and the Netherlands. Patients are diagnosed with a chronic endocrine disorder. Intervention: The study consists of 4 study arms: receiving the YESS! game and toolkit (group YT), receiving the control game and toolkit (group GT), receiving the toolkit only (group T) and receiving regular transition care (group O). Every group will receive regular transition care. The transition toolkit consists of paper cards with assignments, ideas and tips regarding medical self-management. Main study parameters: Primary outcome: the Self-management and Transition to Adulthood with Rx (=treatment) (STARx) questionnaire score 12 months after inclusion in group YT compared to group O. Secondary outcome: the STARx questionnaire score 6 months after inclusion in group YT compared to the other study groups, the STARx questionnaire score 12 months after inclusion in group YT compared to group GT and T and the drop-out rate to the adult outpatient clinic in the first year after the last visit to the paediatric endocrinologist (i.e. one year after the moment of transfer) in group YT compared to groups GT, T and O. Nature and extent of the burden and risks associated with participation: The participants are not exposed to any risks. The YESS! and the control game are safe apps played on a mobile phone or tablet. The burden consists of filling out the STARx questionnaires and playing the YESS! or control game. The questionnaires will be filled out online at home at the start of the study and after 6 and 12 months. Every 6 months the subject has an appointment at the outpatient clinic. The participant can play the YESS! game for a maximum of 15 minutes a day to prevent game addiction. The control game could be played for an unlimited amount of time, but will unlikely cause game addiction since the game is not considered challenging and exciting enough.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Participants complete the STARx self-management questionnaire online at the start, and again at 6 and 12 months. They have an outpatient clinic appointment every 6 months. Participants are randomized to one of four groups and may receive the YESS! mobile game (played up to 15 minutes per day) plus a paper transition toolkit, a control mobile game plus toolkit, the toolkit only, or regular transition care. The main burdens are playing the assigned game (if applicable) and filling out online questionnaires; no invasive procedures are listed in the record.
How the study is structured. A multicentre, randomized, double-masked trial with four parallel groups: YESS! game plus toolkit; control game plus toolkit; toolkit only; or usual transition care. Participants complete online questionnaires at start, 6 months and 12 months while receiving regular clinic follow-up.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The registry says recruitment has not started. When is it expected to open, and can I register interest now?
- The listed sites are in Belgium, Netherlands, Spain, United Kingdom. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on congenital adrenal hyperplasia
Important dates
- Study start
- Dec 1, 2024 (estimated)
- Primary completion
- Dec 1, 2026 (estimated)
- Study completion
- Dec 1, 2026 (estimated)
- Target enrollment
- 160 participants (estimated)
- Last updated on registry
- Sep 7, 2023
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- dr. Laura C. G. de Graaff-Herder
Participating sites (7)
- Ghent University Hospital
Ghent, 9000 · Belgium
- Erasmus Medical Center
Rotterdam, South Holland, 3015 GD · Netherlands
- Laura CG de Graaff, MD, PhD · +31618843010 · l.degraaff@erasmusmc.nl
- Sabine E Hannema
- Hospital Infantil Universitario Niño Jesús
Madrid, 28009 · Spain
- Jesús Argente · jesus.argente@fundacionendo.org
- Queen Elizabeth University Hospital
Glasgow, G51 4TF · United Kingdom
- Royal Hospital for Children
Glasgow, G51 4TF · United Kingdom
- Mohammed G Shaikh · guftar.shaikh@nhs.net
- The Royal London Hospital (Barts Health NHS Trust)
London, E1 1BB · United Kingdom
- Ruben Willemsen · ruben.willemsen@nhs.net
- University College London Hospital (UCL Institute of Child Health)
London, NW1 2PG · United Kingdom
- Gary E Butler · gary.butler@ucl.ac.uk
Terms used on this page · explanations by MedicalUpdates.ai
- follow-up
- The period after treatment or enrolment during which participants are observed or contacted, for example to record side effects or outcomes.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- randomized
- Participants are assigned to the study groups by chance, like a coin toss, rather than chosen by the doctor or the participant. This is done so the groups are comparable.
- Primary outcome
- The main result the study is designed to measure and report on. Other results, called secondary outcomes, are also collected.
- Secondary outcome
- An additional result the study measures alongside the primary outcome, for example quality of life or a laboratory value.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials